Hepatitis Annual Update 2018

In this downloadable slideset, expert faculty provide a comprehensive update on HCV therapy.

Paul Y. Kwo, MD Kristen Marks, MD David R. Nelson, MD Released: May 25, 2018

In this downloadable slideset, expert faculty provide a comprehensive update on managing HCV in special patient populations.

Jordan J. Feld, MD, MPH Nancy Reau, MD Mark S. Sulkowski, MD Released: May 29, 2018

Led by Paul Martin, MD, a panel of experts discusses their management approach to several controversial clinical scenarios, including whether to treat patients with immune-tolerant HBV infection, whether all patients receiving suppressive TDF for the treatment of HBV infection should be switched to TAF, if it is reasonable to discontinue oral therapy in select patients with HBeAg-negative HBV infection who do not have cirrhosis, and whether increased engagement by liver disease specialists will be needed to reach HCV elimination goals by 2030.

Norah Terrault, MD, MPH
Program Director Paul Martin, MD Christian B. Ramers, MD, MPH Nancy Reau, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: July 6, 2018 Expired: July 5, 2019

Led by Christian B. Ramers, MD, MPH, a panel of experts discusses their management approaches to challenging patient case scenarios, including a patient with decompensated cirrhosis and chronic HCV infection, a patient with suspected acute HCV infection and recent injection drug use, a DAA-experienced patient with genotype 1a HCV infection, and a patient with suppressed HBV infection and treated and cured HCV infection who has persistent liver enzyme elevations.

Norah Terrault, MD, MPH
Program Director Paul Y. Kwo, MD Paul Martin, MD Christian B. Ramers, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: July 6, 2018 Expired: July 5, 2019